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Introduction
The incidence of many human diseases, including cancers, 
increases with age (1). The aging process is associated with func-
tional impairment at the tissue, cellular, and molecular levels 
(2). Aging-associated changes are particularly evident in the BM 
of mice and humans, manifesting as reductions in BM density, 
changes in vascularization, and alterations in the composition of 
accessory and structural cells (3).
The function of hematopoietic stem and progenitor cells 
(HSPCs) significantly declines with age in both mice and humans 
(4–7). In competitive transplantation assays, old hematopoietic 
stem cells (HSCs) exhibit reduced reconstitution potential on a 
per-cell basis (a measure of “cellular fitness”) when compared 
with HSCs isolated from young mice. Aged HSCs also exhibit 
altered metabolism and localization in the BM as well as reduced 
BM homing potential upon transplantation (8–10). Aging-associ-
ated hematopoietic defects are particularly apparent in the lym-
phoid lineages, which in mice and humans can be partly attributed 
to the skewing of the HSC repertoire toward myeloid-biased HSCs 
(6, 10–13). Additional studies have indicated that the aged BM 
microenvironment can contribute to reductions in B lymphopoie-
sis (14, 15). Notably, we have previously shown that declining B 
lymphoid progenitor fitness in old mice promotes selection for the 
BCR-ABL oncogene due to its ability to correct aging-associated 
defects in cell signaling (16).
More recently, it has been demonstrated that inflammatory 
cytokines regulate the function of hematopoietic progenitor cells. 
TNF-α and TGF-β (at high concentrations) have been shown to 
suppress HSC activity (17, 18), whereas IFN-α, IFN-γ, and TGF-β 
(at low concentrations) activate HSC proliferation (19–21). More-
over, inflammation has been shown to directly impair B lympho-
poiesis (and thus favor myelopoiesis) by preventing B progenitor 
localization to the IL-7–rich niches required for B cell develop-
ment (22–24). In aged mice, the production of TNF-α by aging- 
associated B cells impairs B lymphopoiesis (14, 25), and the mye-
loid-biasing of the hematopoietic compartment with age is in part 
regulated through the actions of TGF-β1 (18). Whereas inflamma-
tion is important for survival in youth to combat infections and 
repair tissues, it can have adverse effects on aged individuals (26, 
27). Indeed, older humans typically present a subclinical systemic 
chronic inflammatory status termed “inflamm-aging,” which has 
been postulated to contribute to the development of a variety of 
aging-associated diseases such as Alzheimer’s disease, cardiovas-
cular disease, and cancer (28–31).
Current paradigms attribute the association between aging 
and cancer primarily to the progressive accrual of oncogenic 
mutations that are widely thought to be the rate-limiting events 
in the generation of most cancers (32–34). Predominant models 
of carcinogenesis mostly assume that mutations convey defined 
fitness effects on transformed cells; however, this idea contra-
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defined as a measure of the ability of stem/progenitor cells of 
a certain epigenotype/genotype to transmit this type to subse-
quent cell generations).
Given the strong correlations between advanced age, chronic 
systemic inflammation, and cancer incidence in mammals, in this 
study we sought to determine how aging-associated inflamma-
tion impacts lymphoid progenitor populations and how this state 
influences the evolution of leukemias. Using transgenic expres-
sion of two different proteins, α-1-antitrypsin (AAT) and IL-37, in 
order to reduce inflammation in old mice, we show that prevent-
ing aging-associated reductions in B progenitor fitness abrogates 
selection for oncogene-initiated progenitors.
dicts evolutionary theory, which holds that fitness is dictated by 
the interaction of a genotype-defined phenotype with the envi-
ronment (35). Similarly, the somatic mutation theory of aging 
largely attributes age-dependent tissue decline to the accumu-
lation of somatic mutations throughout life (2, 32, 33, 36). Our 
laboratory has computationally modeled fitness changes and 
somatic evolution in HSC pools during life to demonstrate that 
mutation accumulation alone cannot account for either HSC fit-
ness decline or late-life clonal evolution (35). Importantly, these 
modeling studies demonstrate that age-dependent alterations 
in the tissue microenvironment are necessary for both HSC 
fitness decline and clonal evolution (where cellular “fitness” is 
Figure 1. Impaired metabolism, nucleotide anabolism, and cell cycling accompany aging B lymphopoiesis. (A) Nucleotide synthesis GSEA sets were 
derived from microarray analysis of B progenitors isolated from young and old BALB/c mice. Y1, young mouse #1; O1, old mouse #1. (B) Hprt, Gmps, and 
Myc expression in sorted young and old pro–B cells was determined using qPCR. Values represent the mean ± SEM of 4 independent experiments (8 donor 
mice/age group). (C) Young BALB/c mice were injected with 1× PBS or IL-7–neutralizing Abs (αIL-7) every 4 days for 2 weeks, and Pax5 and Hprt expres-
sion was determined by qPCR in B220-purified B progenitors. Values represent the mean ± SEM of 3 independent experiments (6 mice/age group). (D) B 
progenitors were isolated from young and old BALB/c mice, and NMR metabolomics was performed. Values represent the mean ± SEM of 2 independent 
experiments (8 donor mice/age group). (E) ATP and NADH levels were determined in B progenitors isolated from young and old BALB/c mice. Values rep-
resent the mean ± SEM of 3 independent experiments (9 donor mice/age group). (F) Samples used in D were analyzed by mass spectrometry for relative 
nucleotide levels.(G) Young and old BALB/c mice were treated with 1× PBS (Veh.), or young mice were treated with IL-7–neutralizing Abs as described in C, 
and the energy balance of purine nucleotides in B220+ cells was determined by mass spectrometry. Values represent the mean ± SEM of 3 independent 
experiments (4 donor mice/group). (H–J) C57BL/6 mice were injected with EdU, BM was harvested 2 hours later, and cell-cycle analysis in pro–B cells was 
performed. (H) B220+/MAC1+ (B/M) cell ratio. (I) Representative cell-cycle profiles. (J) Normalized x-mean MFI of EdU+ cell populations for pro–B cells. 
Statistical analyses in H and J are relative to the levels observed in 5-month-old mice and represent the mean ± SEM of 3 independent experiments  
(4 donor mice/age group). *P < 0.05, **P < 0.01, and #P < 0.001, by Student’s t test relative to young controls for each experiment. Y, young; O, old.
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ability of key signaling intermediates, and a young nonhematopoi-
etic microenvironment cannot correct aging-associated defects in 
B cell progenitors that develop from the transplanted old HSC.
Given the extensive metabolic changes associated with aging 
B lymphopoiesis as well as the findings of previous studies demon-
strating increased replicative stress and cell-cycle defects in HSCs 
from old mice (39), we determined the consequences of these 
perturbations on cell-cycle progression. Mice of various ages were 
injected with the nucleotide analog 5-ethynyl-2′-deoxyuridine 
(EdU). We observed significant reductions in B lymphopoiesis in 
mice between 14 and 22 months of age, as indicated by a decrease 
in the ratio of B cell (B220+) to myeloid cell (MAC1+) progenitors 
(Figure 1H). Notably, aged pro–B cell progenitors exhibited a sig-
nificant reduction in the rate of S-phase progression (Figure 1, I 
and J); however, we did not observe increased apoptosis in aged 
B progenitor populations (Supplemental Figure 2G). Overall, 
these results reveal that aging B lymphopoiesis is accompanied by 
extensive metabolic changes that culminate in defective cell-cycle 
progression in B cell progenitors. Since these alterations coincide 
with the reduced competitive potential of old B progenitors (40) 
and impairing IL-7R signaling is sufficient to reduce the function 
of B cell progenitors and impair B lymphopoiesis, we conclude that 
these signaling, metabolic, and cell-cycle defects are contributing 
to an age-associated decline in B progenitor fitness.
Oncogenic mutations correct aging-associated functional defects 
in B progenitors. Given that BCR-ABL expression corrects defec-
tive IL-7R–mediated signaling in aged B cell progenitors, leading to 
increased leukemogenesis in aged backgrounds (16), we determined 
whether BCR-ABL expression reverses aging-associated defects in 
key genes involved in metabolism and DNA replication. Since BCR-
ABL expression activates RAS and MYC (41), we also asked whether 
the NRASV12 and MYC oncogenes are adaptive in aged backgrounds 
by correcting aging-associated B progenitor fitness defects.
Using the Ba/F3 pro–B cell line, we found that directly inhib-
iting cytokine receptor signaling on B lineage cells in vitro was 
sufficient to reduce the expression of key nucleotide synthe-
sis genes, as reducing IL-3–mediated stimulation of the Ba/F3 
pro–B cell line impaired STAT5 phosphorylation (Figure 2A) and 
expression of Myc (Figure 2B) and Hprt (Figure 2B). Importantly, 
the expression of oncogenic BCR-ABL, NRASV12, and Myc main-
tained STAT5 phosphorylation and Myc and Hprt expression lev-
els in Ba/F3 cells despite cytokine withdrawal (Figure 2, A and 
B), indicating a direct ability of these oncogenes to rescue cyto–
kine receptor signaling defects.
In order to study oncogenic adaptation in vivo, hematopoi-
etic progenitor cells from young and old mice were retrovirally 
transduced to introduce the oncogenes BCR-ABL, NRASV12, or 
Myc and transplanted into sublethally irradiated young recipient 
mice. Three weeks after transplantation, oncogene or vector bear-
ing pro–B cell progenitors (GFP+) were flow sorted from recipient 
mice and their signaling and gene expression profiles determined. 
The expression of oncogenic BCR-ABL, NRASV12, and Myc each led 
to restoration of p-STAT5 activation in old pro–B progenitors (Fig-
ure 2C). In contrast, expression of these oncogenes did not lead 
to significant alterations in p-STAT5 levels in young pro–B cells, 
for which signaling was already high. We also observed that onco-
genic BCR-ABL, NRASV12, and Myc restored youthful expression 
Results
Metabolic and cell-cycle defects accompany aging B lymphopoiesis. 
In order to understand the mechanism underlying declining B 
lymphopoiesis in old age, we performed microarray analysis on 
combined pro– and pre–B cell populations isolated from young 
(2-month-old) and old (24-month-old) mice. Gene set enrich-
ment analysis (GSEA) revealed that aging B lymphopoiesis is 
accompanied by significant reductions in purine and pyrimidine 
metabolism (Figure 1A and Supplemental Figure 1A; supple-
mental material available online with this article; doi:10.1172/
JCI83024DS1). The aging-associated decreases in the expression 
of the key purine synthesis genes hypoxanthine-guanine phospho-
ribosyltransferase (Hprt) and guanine monophosphate synthase 
(Gmps) were confirmed using quantitative PCR (qPCR) analysis in 
sorted pro–B cell populations (Figure 1B).
IL-7 signaling decreases with age in B cell progenitors (16, 37). 
Similar to previous reports (38), inhibiting IL-7R signaling by inject-
ing mice with IL-7 neutralizing Abs (αIL-7) significantly decreased 
the expression of Pax5 in pro–B cells (Figure 1C). Notably, reducing 
IL-7R signaling also significantly decreased Hprt gene expression 
in pro–B cells (Figure 1C), suggesting that aging-associated reduc-
tions in purine synthesis gene expression can be explained, at least 
in part, by an impairment of IL-7R signaling.
Our microarray analysis also indicated that mitochondrial 
dysfunction accompanied aging B lymphopoiesis (P = 7.01 × 10–7 
for mitochondrial dysfunction using Ingenuity Pathway Analysis 
[IPA]), suggesting that metabolic changes also accompany aging 
B lymphopoiesis. Indeed, nuclear magnetic resonance (NMR) 
analysis revealed significant decreases in total nucleotide and 
adenosine levels in aged B cell progenitors (Figure 1D), consistent 
with reduced purine synthesis resulting from decreased expres-
sion of genes such as Hprt and Gmps. Furthermore, other meta-
bolic intermediates such as citrate (a key TCA cycle intermedi-
ate) and glutamine (an amino acid that can enter the TCA cycle) 
levels were significantly decreased with age in B cell progenitors 
(Figure 1D). Importantly, lactic acid (a marker for increased gly-
colytic output and mitochondrial impairment) was also found to 
be increased in old B cell progenitors (Figure 1D). These meta-
bolic perturbations coincided with significant reductions in ATP, 
reduced ATP/ADP and GTP/GDP ratios, elevated NADH levels, 
and significant reductions in mitochondrial ROS levels in aged B 
cell progenitors (Figure 1, E and F, and Supplemental Figure 1B). 
Reduced ATP/ADP and GTP/GDP ratios (reduced energy bal-
ances) could be recapitulated in B cell progenitors in young mice 
by inhibiting IL-7R signaling (Figure 1G).
Analysis of total STAT5a/b protein levels in B cell progen-
itors revealed that aged pro– and pre–B cell progenitors had sig-
nificantly lower STAT5a/b protein levels relative to their young 
counterparts (Supplemental Figure 2A), correlating with an over-
all reduction in phosphorylated STAT5a (p-STAT5a) protein levels 
(Supplemental Figure 2B). Notably, impairments in B cell produc-
tion, STAT5-mediated signaling, and the expression of key genes 
involved in purine synthesis (Gmps), B cell development (Ebf), and 
proliferation (Myc) were not reversed by transplantation into irra-
diated young mice (Supplemental Figure 2, C–E). These observa-
tions indicate that aging-associated reductions in IL-7R signaling 
in B cell progenitors result, at least in part, from the reduced avail-
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ing a competitive advantage within poorly fit old B progenitor 
pools, promotes increased leukemogenesis. Lethally irradiated 
young mice were prepopulated with young or old BM cells to cre-
ate young and aged hematopoietic systems, respectively, and then 
transplanted with either young or old BM progenitor cells trans-
duced with the NRASV12 and Myc oncogenes. Oncogene-driven 
restoration of B progenitor function in old, but not young, pro–B 
cells led to increased NRASV12- and Myc-mediated leukemogene-
sis in aged backgrounds. In contrast, leukemogenesis was largely 
levels of Hprt (Figure 2D) and endogenous Myc (Figure 2E). Inter-
estingly, the defective expression of the B lineage specification 
genes Ebf (Figure 2F) and Pax5 (Supplemental Figure 2F) in aged B 
cell progenitors was not restored by these oncogenes. From these 
results, we conclude that BCR-ABL, NRASV12, and Myc expression 
restores the key parameters of fitness, but not the differentiation 
potential, of aged B progenitors.
We next determined whether NRASV12- and Myc-mediated 
restoration of impaired fitness in aged B progenitors, by provid-
Figure 2. Oncogenic mutations correct aging-associated functional defects in B progenitors, leading to increased leukemogenesis. (A) Ba/F3 cells 
expressing vector (V) or oncogenes (BCR-ABL, NRASV12, Myc) were grown in various concentrations of IL-3 for 24 hours, and STAT5 activation in these cells 
was determined by flow cytometry. (B) Ba/F3 cells were grown overnight in media containing or lacking IL-3, and expression levels of Myc and Hprt in these 
cells were determined by qPCR. Values in A and B represent the mean ± SEM of 3 independent experiments (9 total samples). (C–F) c-KIT+ BM cells were 
isolated from young (2-month-old) or old (24-month-old) mice, retrovirally transduced to express vector or oncogenic BCR-ABL, NRASV12,, or Myc (each with 
coexpressed GFP), and transplanted into sublethally irradiated young BALB/c mice. Three weeks after transplantation, mice were sacrificed, and STAT5 
activity (C) and mRNA levels of Hprt, Myc, and Ebf (D–F) were determined in vector-expressing or oncogene-expressing pro–B cell progenitors. Values in 
C–F represent the mean ± SEM for more than 5 mice per group. (G and H) Young mice were lethally irradiated and transplanted with either 2 × 106 young or 
old whole BM cells. Four days later, mice reconstituted with young or old BM cells were transplanted, respectively, with young or old c-KIT+ cells expressing 
oncogenic NRASV12 or Myc. Leukemia-free survival is plotted using Kaplan-Meier graphs. Most mice developed B220+CD43+ pro–B cell–like acute lympho-
blastic leukemia (ALL) (87% and 80% for NRAS- and Myc-driven leukemias, respectively, on the old backgrounds). (I) Young or old mice were treated with 
busulfan and transplanted with young or old c-KIT+ cells expressing oncogenic NRASV12. Leukemia-free survival is plotted using Kaplan-Meier graphs. 
Values in G and H represent the mean ± SEM of 2 independent experiments, with more than 15 mice per group in total, and values in I represent 5 mice per 
treatment group. (A–F) **P < 0.01 and #P < 0.001, by Student’s t test . In C–F, oncogene-bearing samples were compared with vector-expressing controls 
(old to old). (G–I) **P < 0.01 and #P < 0.001, by Cox proportional hazards test. BMT, BM transplantation.
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of aged mice (Figure 3, C and D). Furthermore, both IPA (Figure 
3E) and GSEA (Figure 3F) revealed that the expression of TNF-α 
and its target genes was significantly increased in aged B cell pro-
genitor populations (P = 4.23 × 10–5 for TNF-α stimulatory pathways 
using IPA). These findings were corroborated by flow cytometric 
analyses, which revealed that the production of TNF-α significantly 
increased with age in pro–B cell progenitors (Supplemental Figure 
4B). In addition, BM stromal cell cultures from old mice exhibited 
elevated production of IL-1β and IL-6 relative to the levels detected 
in cultures from young mice, while BM B cell lineage cultures from 
old mice only exhibited increased IL-6 production (Supplemental 
Figure 4, C–E). In addition to increased Tnfa mRNA expression, 
Ifnz and IFN-α–inducible protein 27 (Ifi27) mRNA expression lev-
els were also evident in sorted pro–B cell progenitors isolated from 
old mice (Figure 3G). Similarly, Muc5b, which has been shown to be 
activated in a variety of cell types in response to inflammation (43), 
was only found to be expressed in aged, but not young, pro–B cell 
progenitors. These experiments revealed that aging is associated 
with increased inflammation in the BM and within resident B cell 
progenitors. Contrasting with the correction of aging-associated 
fitness defects in pro–B cells (Figure 2), the expression of BCR-ABL 
and NRASV12 significantly increased the expression of Tnfa in aged 
pro–B cell progenitors (Figure 3H). Notably, the expression of BCR-
ABL, NRASV12, or Myc did not elicit TNF-α production from young 
pro–B cell progenitors (Figure 3H). Thus, oncogene expression can 
actually exacerbate the expression of inflammatory cytokines spe-
cifically in old progenitors.
Ectopically promoting inflammation in young mice phenocop-
ies aging-associated B lymphopoiesis. We asked whether increas-
ing inflammation is sufficient to impair B cell progenitor fitness. 
To this end, young mice were injected with LPS or recombinant 
TNF-α every 4 days for a period of 2 weeks. As a control, we 
injected αIL-7 to impair B lymphopoiesis. After 2 weeks of treat-
ment, we observed significant reductions in the percentages of 
pro–, pre–, and immature B cells in the BM of mice treated with 
αIL-7 or inflammatory mediators (LPS or TNF-α) (Figure 4A), con-
sistent with previous results (22–24). Importantly, acute inflam-
mation also significantly decreased expression levels of the B 
lineage specification genes Pax5 and EbF (Figure 4B) as well as 
expression of the purine synthesis genes Hprt and Gmps (Figure 
4C) in B cell progenitors, providing molecular insight into reduced 
B progenitor fitness with old age. Collectively, these data demon-
strate that induction of inflammation in young mice mirrors the B 
lymphopoiesis defects observed in old mice.
Aging in most vertebrates is commonly associated with low-
grade, chronic inflammation (31). We investigated whether the 
chronic inflammation that we observed in old mice can underlie 
their B lymphopoiesis defects. We monitored B cell development 
in TNF-αΔARE mice, which have a mutation in the Tnfa 3′-UTR, 
removing regulatory adenylate-uridylate–rich (AU-rich) elements 
and leading to increased constitutive TNF-α expression. These 
mice exhibit heightened susceptibility to chronic inflammatory 
diseases such as rheumatoid arthritis and Crohn disease (44, 45). 
Young TNF-αΔARE mice had significantly (~5-fold) increased circu-
lating TNF-α levels (Figure 4D). B lymphopoiesis was significantly 
reduced in young TNF-αΔARE mice, coinciding with an increased 
frequency of myeloid cells (Figure 4, E and F). Furthermore, 
suppressed in young hematopoietic contexts (Figure 2, G and H). 
Thus, provision of the oncogenic drivers is insufficient to induce 
leukemias, as the leukemic potential of the oncogenic mutations 
is only fully realized in the aged hematopoietic context. Notably, 
we have previously shown that the differential ability of BCR-ABL 
to induce leukemias in young and old hematopoietic backgrounds 
does not require an intact adaptive immune system (16).
We then asked whether the age of the host would similarly 
impact leukemogenesis; specifically, would transplantation of 
NRASV12-transduced old BM into a young recipient still efficiently 
induce leukemias? In order to reduce the transplant-induced 
affects on the host BM microenvironment, we used busulfan rather 
than γ irradiation to condition recipient mice prior to transplanta-
tion with NRASV12-transduced BM. Busulfan conditioning induced 
a mild inflammatory response, as indicated by transient increases 
in BM and serum IL-6 and TNF-α levels, which returned to base-
line by day 5 after treatment (Supplemental Figure 3, A–D). BM 
hematopoietic cell populations returned to homeostatic numbers 
by day 5 after busulfan treatment (Supplemental Figure 3, E–G). In 
contrast, sublethal irradiation induced greater and more prolonged 
increases in these cytokines, and B lymphopoiesis was still highly 
suppressed on day 5 after irradiation (Supplemental Figure 3, A–G). 
Importantly, transplantation of oncogenic NRASV12-transduced old 
BM progenitors into young mice resulted in significantly less leuke-
mia than their transplantation into old recipient mice (Figure 2I). 
We tracked the frequencies of NRASV12-expressing (GFP+) B cells 
and myeloid cells in peripheral blood over the course of the exper-
iment and found that the percentage of B lineage cells express-
ing NRASV12 was only maintained and amplified in old recipient 
mice, but not in young recipient mice, even when donor progeni-
tor cells were old (Supplemental Figure 2, H–K). Thus, the age of 
the microenvironment may be more important than the age of the 
cells receiving the oncogenic hit in leukemia development. In total, 
these results reveal that oncogenic BCR-ABL, NRASV12, and Myc 
expression correct functional defects in aged pro–B cells, leading 
to increased selection in aged hematopoietic backgrounds, with 
subsequent progression to B-lineage leukemias.
Increased inflammation in the BM with age coincides with 
decreased expression of genes regulating cell-cycle progression in B pro-
genitors. Since inflammation increases with age in most mammals 
(31) and regulates the function of HSPCs (42), we explored the 
relationship between aging-associated increases in inflammation 
and B lymphopoiesis. Principal component analysis (PCA) of the 
microarray data indicated that gene expression profiles for B pro-
genitors isolated from individual young mice exhibited low intra-
group variability; in contrast, B progenitors isolated from old mice 
exhibited divergent gene expression profiles (Figure 3A). Notably, 
reductions in E2F and MYC target genes, including genes involved 
in nucleotide synthesis and cell-cycle progression, coincided with 
increases in the inflammatory signature (Figure 3B). In order to 
determine the kinetics of altered inflammation with age, we per-
formed ELISAs for inflammatory cytokines on serum and BM 
aspirates taken from young, middle-aged, and old mice. Whereas 
analyses of serum samples revealed only a trend toward elevated 
TNF-α and IL-6 serum levels in middle-aged and old mice relative 
to levels in young mice (Supplemental Figure 4A), both of these 
cytokines were consistently and significantly increased in the BM 
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Figure 3. Increased inflammation in the BM with age coincides with decreased expression of genes regulating cell-cycle progression in B progenitors. 
(A) PCA of the microarray data was generated using the Partek Genomics Suite. (B) Gene expression profiles from the microarray analysis performed on  
B cell progenitors isolated from young and old mice were analyzed by GSEA for the expression of genes regulated by E2F and MYC and of those involved in 
inflammatory processes. (C and D) BM aspirates were collected from young (Y; 2-month-old), middle-aged (M; 14-month-old), and old (O; 24-month-old) 
mice, and IL-6 (C) and TNF-α (D) levels were determined using ELISA. Values represent the mean ± SEM of 2 independent experiments, with more than 6 
mice per age group. (E) Network analysis of the microarray data was performed using IPA software, which identified TNF-α as an important cytokine that 
increases in aged B progenitors. (F) Heatmap showing a subset of the inflammatory genes shown in B. (G) Pro–B cell progenitors from young (2-month-
old) and old (24-month-old) mice were sorted, and expression levels of inflammatory genes (Tnfa, Ifnz, and Ifi27) or of those regulated by inflammation 
(e.g., Muc5b) were determined by qPCR. (H) Expression levels of TNF-α in sorted young or old pro–B cells expressing vector or oncogenic BCR-ABL, NRASV12, 
or Myc (all GFP+) were determined using qPCR. Values in G and H represent the mean ± SEM of 4 independent experiments, with more than 10 mice per age 
group. #P < 0.001, by Student’s t test relative to young controls. ND, not determined.
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chronic TNF-α exposure significantly reduced Hprt and Gmps 
gene expression levels in sorted pro–B cells (Figure 4G). We con-
clude that chronic TNF-α exposure in young mice impairs the fit-
ness of pro–B cells in a manner similar to that observed with aging.
Reducing inflammation prevents aging-associated fitness defects 
in B cell progenitors. We used transgenic mice that express either 
human AAT or human IL-37 to determine whether either of these 
antiinflammatory mediators could protect against age-associated 
fitness reductions in B progenitors. AAT is a serum serine pro-
tease inhibitor with potent antiinflammatory activity. Transgenic 
expression of human AAT under the surfactant protein C promoter 
results in low circulating levels of AAT (46, 47). Nevertheless, 
mice transgenic for AAT (AATtg) exhibit a remarkable resistance 
to a broad spectrum of inflammatory and immunological chal-
lenges (48). IL-37 is an antiinflammatory member of the IL-1 fam-
ily that broadly inhibits innate inflammation (49). IL-37 transgenic 
(IL-37tg) mice expressing human IL-37 are protected in models 
of endotoxin shock, colitis, and ischemia reperfusion injury (50, 
51). Strikingly, the aging-associated increases in TNF-α, IL-6, and 
IL-1β levels in the BM and serum of 20-month-old mice were pre-
vented by transgenic expression of either AAT or IL-37 (Figure 5).
We observed significant reductions in the number of pro–, 
pre–, and immature B cell populations in aged AATtg (Figure 6A) 
and IL-37tg (Figure 6D) mice that were comparable to the reduc-
tions seen in nontransgenic controls. However, pro–B cells from 
older AATtg or IL-37tg mice had STAT5 activation levels similar 
to those observed in young mice, contrasting with cells from older 
nontransgenic mice (Figure 6, B and E). Furthermore, AAT and 
IL-37 expression prevented the aging-associated reductions in 
Hprt, Gmps, and Myc gene expression in aged pro–B cells (Figure 
6, C and F). AAT expression also decreased the proinflammatory 
state of aged pro–B cells, as indicated by significant decreases in 
the expression levels of TNF-α and IFNip27. Combined, these 
data suggest that aged, antiinflammatory microenvironments pre-
serve the fitness of B cell progenitors, while failing to prevent the 
aging-associated reductions in B progenitor frequency.
Figure 4. Induction of inflammation promotes functional decline in B progenitors. (A–C) Young mice were injected every 4 days for 2 weeks with PBS 
(vehicle), αIL-7–neutralizing Abs, LPS, or recombinant TNF-α. After 2 weeks of treatment (3 injections total), the mice were sacrificed and the percentage 
of B progenitors in the BM determined using flow cytometry. Expression levels of B lineage–specification genes (B) and purine synthesis genes (C) were 
determined using qPCR. Values in A–C represent the mean ± SEM for 5 mice per treatment group. (D–G) Serum TNF-α levels in 5-month-old TNF-αΔARE 
mice and their littermate controls were measured by ELISA (D), frequencies of B cell (B220+) and myeloid (MAC1+) progenitor cells in BM were determined 
by flow cytometry (E and F), and mRNA levels of purine synthesis genes in pro–B cells were determined by qPCR (G). Values represent the mean ± SEM of 
3 independent experiments, with more than 9 mice per group. *P < 0.05, **P < 0.01, and #P < 0.001, by Student’s t test relative to PBS-injected mice or 
littermate controls. LC, littermate control.
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cating that aging-related inflammation is a key driver of oncogenic 
adaptation in B progenitors.
STAT5 activity is reduced in host (CD45.2+) pro–B cells isolated 
from old mice, and this decline was prevented in host pro–B cells 
isolated from aged AATtg mice (Figure 7E). We asked whether the 
age and inflammatory status of the host had an impact on fitness 
parameters for B progenitors that developed from transplanted 
young BM (CD45.1+). Indeed, young CD45.1+ pro–B cell progenitors 
that developed in aged recipient mice also exhibited significantly 
reduced STAT5 activation, but not if the recipients were old AATtg 
mice (Figure 7F; donor CFP+ cells). Similarly, expression levels of 
Hprt, Gmps, and Stat5b were all reduced in the young donor pro–B 
cells that developed in aged recipient mice, but not if the recipients 
were AATtg or young (Figure 7, G and H and Supplemental Figure 
5B). Thus, these key fitness parameters for B progenitors are dic-
tated by the age and inflammatory status of the host microenviron-
ment. Strikingly, NRASV12 expression restored p-STAT5 activation 
and mRNA levels of Hprt, Gmps, Myc, and Stat5b in pro–B cells 
in aged recipients to the levels observed in young recipients (Fig-
ure 7F; donor GFP+ cells), providing a rationale for NRAS activa-
tion-dependent adaptation in the aged/inflammatory background. 
Notably, ERK activation in B progenitor cells was not affected by 
Reducing inflammation in aged backgrounds prevents selection for 
oncogenic NRASV12. We next determined whether reducing inflam-
mation in aged mice altered the selection for oncogenically initi-
ated cells. Young and old AATtg mice and age-matched controls 
were injected with the same pool of young BM progenitor cells 
transduced with retroviral vectors expressing NRASV12 plus GFP 
or cyan fluorescent protein (CFP) only (Figure 7A). Thus, it is the 
age and inflammatory status of the host microenvironment, not 
the cells expressing the oncogene or vector control, that is being 
varied. Notably, expression of the control CFP vector by periph-
eral B cells was not influenced by the host’s age or genetic back-
ground and did not exhibit significant changes over time (Figure 
7B), indicating that homing of transduced cells and their mainte-
nance in the host (including potential immune rejection) were not 
impacted by the recipient mouse’s age or AAT transgene expres-
sion. In striking contrast, we observed clear and exclusive selec-
tion for NRASV12 expression in the B cell lineage in old recipients, 
but not in young or old AATtg recipients (Figure 7C), which mir-
rored the selection for NRASV12 expression in BM B progenitors 
only in the nontransgenic old recipients (Figure 7D). Thus, selec-
tion for NRASV12 expression was completely prevented in B progen-
itor pools in the aged antiinflammatory AATtg backgrounds, indi-
Figure 5. Proinflammatory cytokines are reduced in old antiinflammatory transgenic mice. ELISAs for TNF-α, IL-6, and IL-1β were performed on BM aspi-
rates and serum collected from young (2-month-old) and old (20-month-old) littermates, old AATtg mice (A and B), and old IL-37tg mice (C–E). Values rep-
resent the mean ± SEM of 2 independent experiments (6 mice total). *P < 0.05, **P < 0.01, and #P < 0.001, by Student’s t test relative to young controls.
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Hprt and Gmps gene expression levels similar to those detected in 
pro–B cells in young recipients, and NRASV12 expression prevented 
reductions in these fitness parameters in pro–B cells that developed 
in aged littermate control mice (Figure 8, B and C). In all, our exper-
iments using both AATtg and IL-37tg models indicate that key fit-
ness parameters of B cell progenitors can be dictated by the state 
of the microenvironment (age and inflammatory status) and that 
NRAS activation can rescue defects that result from aged/inflam-
matory microenvironments, facilitating clonal expansion of onco-
genically initiated B progenitors.
Discussion
Aging is the single most important prognostic factor associated 
with the development of many diseases including cancer (1). 
The results described here demonstrate that aging-associated 
increases in inflammation negatively impact the development 
and function of B progenitor cells, including reductions in key 
indicators of cell fitness. Importantly, using two different, natu-
the microenvironment in which the cells developed (Supplemen-
tal Figure 5A). AAT also prevented age-dependent increases in the 
expression of the inflammatory mediators TNF-α, IFNip27, and 
MUC5B in B progenitors (Figure 7H and Supplemental Figure 5B). 
Note that we were unable to analyze NRASV12-initiated pro–B cells 
in the young or AATtg backgrounds, as these cells were not detect-
able above background levels (Figure 7D).
To corroborate these results using an alternative means to 
dampen age-dependent inflammation, we used IL-37tg mice. Simi-
lar to the above-described methods, young and old IL-37tg mice and 
age-matched controls were injected with the same pool of young 
BM progenitor cells transduced with retroviral vectors expressing 
NRASV12 plus GFP or CFP only. Expression of IL-37 in aged mice 
also prevented the selection of oncogenic NRASV12-expressing B 
progenitor cells (Figure 8A). Selection for NRASV12 was not observed 
in myeloid lineage fractions (Supplemental Figure 5C). Similar to 
findings in old AATtg recipients, young pro–B cell progenitors that 
developed in aged IL-37tg mice exhibited STAT5 activation and 
Figure 6. Reducing inflammation prevents declines in aging-associated B progenitor fitness. BM from young (2-month-old) and old (20-month-old)  
littermate and AATtg and IL-37tg mice was analyzed for the frequency of B cell progenitor populations (A and D). Activation of STAT5, STAT3, ERK, and 
STAT1 in pro–B cells was determined by flow cytometry (B and E). mRNA expression of genes involved in cell-cycle regulation and inflammation in sorted 
pro–B cells was determined by qPCR (C and F). Values represent the mean ± SEM of 2 independent experiments, with more than 5 mice per group.  
*P < 0.05 and #P < 0.001, by Student’s t test relative to young controls for each experiment. 
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cytokines on B progenitor fitness in aged backgrounds, BCR-ABL 
and oncogenic NRASV12 expression is associated with increased 
expression of inflammatory cytokines in old pro–B cells, per-
haps further impairing the fitness of competing nononcogene-
expressing progenitors (consistent with previous results in HSCs, 
refs. 55–57). We observed that either acute or chronic inflamma-
tion was sufficient to suppress key factors regulating normal B 
cell development (Pax5 and Ebf) and function (Hprt and Gmps), 
resulting in significant decreases in B lymphopoiesis and pheno-
copying the aging process. From these studies, we conclude that 
inflammatory mediators negatively regulate B lymphopoiesis 
and accelerate reductions in B progenitor fitness, suggesting that 
chronic inflammation promotes B progenitor fitness impairments 
that manifest in old age.
Heterochronic parabiosis experiments in mice indicate that 
the aging process, for some organs and tissues, is substantially 
rally occurring molecules to reduce inflammation in old mice, we 
show that preventing aging-associated reductions in B progeni-
tor fitness abrogates selection for NRASV12-initiated progenitors. 
These studies highlight how inflammation-induced alterations 
in the adaptive landscape in old age govern the selection of onco-
genically initiated cells and, ultimately, leukemogenesis within 
hematopoietic progenitor cell populations (Figure 8D).
In recent years, there has been growing interest in identifying 
factors that regulate the aging process (8, 52, 53). We observed 
aging-associated increases in TNF-α, IL-6, and IL-1β levels in the 
BM of old mice. Previous studies demonstrate that aged BM stro-
mal cells and mature B cells that accumulate in the BM are two 
sources of inflammation that manifest with age (25, 54). In this 
study, we further demonstrated that aged pro B cell progenitors 
also produce proinflammatory cytokines such as TNF-α. Notably, 
in addition to providing resistance to the effects of inflammatory 
Figure 7. Reducing inflammation in aged AATtg mice suppresses selection for oncogenic NRASV12–expressing B progenitors. (A) Experimental over-
view. (B and C) Frequencies of young, vector-expressing (CFP+) cells (B) or young, NRASV12-expressing (GFP+) cells (C) in the peripheral blood of recipient 
mice were monitored for 2 months after transplantation. (D) After 2 months, mice were sacrificed, and the frequencies of NRASV12-expressing pre–B cell 
progenitors in the BM of recipient mice were determined by flow cytometry. LD, limit of detection. (E) Recipient pro–B cells (CD45.2+) were analyzed by 
flow cytometry for STAT5 and ERK activation. (F) STAT5 activation in donor pro–B cells (CD45.1+) expressing vector (CFP+) or NRASV12 (GFP+) was analyzed 
using flow cytometry. (G and H) Expression levels of the indicated genes in sorted donor (CD45.1+) pro–B cells expressing vector (V) or NRASV12 (RAS) were 
determined by qPCR . Values in B–H represent the mean ± SEM, with more than 5 mice per group. (B–E and G) #P < 0.001, by Student’s t test relative to 
young controls. (F and H) *P < 0.05, **P < 0.01, and #P < 0.001, by 1-way ANOVA. Ctrl, control.
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progenitors. Interestingly, we still observed a marked decline in 
B progenitor numbers in aged AATtg and IL-37tg mice. These 
results suggest that this decline in B lymphopoiesis may be an 
evolved program that reduces B cell production once a diverse B 
cell repertoire has developed during youth. The aging-associated 
biasing of hematopoiesis toward myelopoiesis may be advan-
tageous in order to better combat infections and repair tissue 
injury. Nonetheless, we found that both AAT and IL-37 expres-
sion prevented functional impairment in IL-7R signaling and 
the expression of purine synthesis genes in pro–B cell progeni-
tors. Therefore, the late-life decline in the function of HSPCs 
(reduced fitness on a per-cell basis) can, in good measure, be 
explained by inflammation that increases late in life, beyond the 
period when reproduction is likely and thus largely outside the 
influence of natural selection.
In our mouse models, we observed selection for the tested 
oncogenic mutations within old B progenitor populations, lead-
ing to the development of B-lineage leukemias. This selection 
was not observed in young hematopoietic backgrounds due to 
the inability of oncogenic mutations to significantly improve the 
fitness of young B progenitor cells (thus, the highly fit B progen-
itors in young microenvironments provide effective competition 
influenced by non–cell-autonomous factors (52, 53). Previous 
studies have shown that both cell autonomous and non–cell- 
autonomous (microenvironmental) factors contribute to hemato-
poietic aging, including functional changes in HSCs and B lymp-
hopoiesis (40, 58, 59). Indeed, we show that young BM progeni-
tors transplanted into old mice (mildly conditioned with busulfan) 
produce B progenitors with signaling defects that mirror those 
of old progenitors, unless the old recipient mice express antiin-
flammatory mediators. Thus, the age and inflammatory status of 
the host mouse dictates the fitness of B progenitors produced by 
young HSCs in the host BM microenvironment. Nonetheless, our 
results also demonstrate that B lymphopoiesis derived from old 
HSCs transplanted into young mice still maintains aging-associ-
ated fitness defects, as indicated by substantial reductions in IL-7–
mediated signaling and the expression of key metabolic and DNA 
replication genes. The inability of a young microenvironment to 
reverse aging-associated defects in hematopoiesis may result 
from substantial aging-associated genetic and epigenetic changes 
in HSPC populations (39, 60–62), even when caused by cell- 
extrinsic factors such as inflammation.
Focusing on inflammation, we asked how age-dependent 
changes in the microenvironment could alter the fitness of B cell 
Figure 8. Reducing inflammation in aged IL-37tg mice abrogates NRASV12-mediated oncogenesis. Young and old (2-month-old and 20-month-old, 
respectively) littermate (LC) or IL-37tg mice were transplanted with young NRASV12-expressing cells, as in Figure 7A. Three months after transplantation, 
BM was analyzed by flow cytometry for (A) the frequency of NRASV12-expressing cells in B progenitor cell populations and (B) activation of STAT5 and ERK 
in pro–B cells expressing NRASV12 (red-outlined gray boxes) or not expressing the oncogene. (C) mRNA levels of Hprt, Gmps, and Myc in sorted pro–B cells 
were determined by qPCR (note: NRASV12-initiated cells only expanded in the old littermate control mice). (D) Model for how aging and aging-associated 
inflammation regulate progenitor cell fitness and oncogenesis. Values in A–C represent the mean ± SEM, with more than 5 mice per group. *P < 0.05 and 
#P < 0.001, by Student’s t test relative to young controls.
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mation. Overall our study indicates that dampening inflamma-
tion in older populations may reduce aging-associated functional 
impairment in hematopoiesis, which in turn may reduce leukemia 
incidence in these populations by preventing the selection for 
oncogenically initiated cells.
Methods
Microarray data were deposited in the NCBI’s Gene Expression Omni-
bus (GEO) database (GEO GSE67827). Microarray, mass spectrome-
try, and NMR methods are provided in the Supplemental Methods.
Mice
BALB/c and C57BL/6 mice of different ages were purchased from 
the National Institute of Aging (NIA) or the National Cancer Institute 
(NCI). CD45.1 congenic mice (B6.SJL-PtprcaPepcb/BoyCrCrl) were 
purchased from Charles River Laboratories. TNF-αΔARE, AAT, and 
IL-37 transgenic mice were backcrossed onto a C57BL/6 background 
for more than 10 generations, and both transgene-positive and trans-
gene-negative littermates were aged in-house. Male and female mice 
from each strain were used in these studies.
Retroviral transduction and BM transplantation
Retroviral transductions and BM transplantations were performed 
as previously described (84). The retroviral murine stem cell virus–
ires-GFP (MSCV-ires-GFP) (MiG), MiG-BCR-ABL, MiG-RAS, MiG-
Myc, and MSCV-ires-CFP (MiC) vectors were used to introduce the 
respective genes into MACS-purified (Miltenyi Biotec) murine c-KIT+ 
hematopoietic progenitor cells. These cells were transduced with 
MiG viruses in nonadhesive 6-well plates by incubation at 37°C for 
2 hours in the presence 8 μg/ml polybrene and 20 μg/ml stem cell fac-
tor, followed by the spin-fection technique (centrifugation at 910 g for 
2 hours). Cells were then washed once with 1× PBS and transplanted 
into conditioned recipient mice.
Mice were condition using sublethal irradiation (5 Gy), lethal irra-
diation (10 Gy split dose), or busulfan (25 mg/kg) and injected with 
transduced cells 2–4 days after treatment (depending on the condi-
tioning protocol). In experiments in which recipient mice were lethally 
irradiated (Figure 2, G and H), mice were injected with 2 × 106 unsorted 
BM cells from young (2-month-old) or aged (22- to 24-month-old) 
donor mice (prepopulated with young or aged competitors, respec-
tively). Before lethal irradiation, mice were deprived of food overnight 
to reduce small intestinal cytotoxicity. Four days after prepopulation, 
2 × 105 MiG-transduced c-KIT+ hematopoietic progenitor cells were 
then transplanted i.v. into recipient mice.
Inflammation-inducing and IL-7–neutralizing experiments
IL-7 neutralization experiments were performed as previously 
described (16). In these experiments, IL-7–neutralizing Abs were 
injected at a dose of 0.5 mg/mouse every 4 days until the experiment 
was terminated. In the experiments described in Figure 4, LPS was 
injected at a dose of 1 mg/kg, and recombinant TNF-α was injected at a 
dose of 5 μg/mouse every 4 days until the experiment was terminated.
EdU analysis of B progenitor populations
EdU analysis of B cell progenitor populations was performed using the 
Click-iT EdU Alexa Fluor 647 Imaging Kit (Life Technologies; catalog 
C10634). C57BL/6 mice were injected i.p. with EdU (2 mg/mouse, 
to limit the expansion of oncogenically initiated progenitors). 
Notably, hematopoietic malignancies of the B lineage predomi-
nate in older mice, while in elderly humans, both B lymphoid and 
myeloid leukemias are common (63, 64). B lymphoid leukemias 
are also common in young children, and infections and the asso-
ciated inflammation have been proposed to play a role in their 
development (65). Whether in humans or mice, contexts that lead 
to reduced fitness of stem/progenitor cells would be expected to 
lead to selection for adaptive oncogenic events in these stem and 
progenitor cell populations and to malignancies of correspond-
ingly different types.
Inflammation has been associated with the progression of 
many solid tumors. Its actions in promoting tumorigenesis have 
largely been attributed to the ability of inflammatory cells to cre-
ate an immune-suppressive microenvironment, promote metas-
tasis, and enhance the protumorigenic phenotypes of cancer cells 
including proliferation, survival, and invasion (66, 67). Notably, 
our studies indicate that inflammation can promote selection 
for oncogenic events in HSPCs by suppressing overall progeni-
tor fitness, providing a context that favors oncogenic adaptation. 
These findings complement emerging studies that have shown 
increased hematopoietic clonal evolution (including for clones 
with known oncogenic drivers) in the elderly (68–72). Inflamma-
tion has also been proposed to contribute to the genesis of mye-
loproliferative disorders that are almost exclusively present in the 
elderly (73, 74), and increased oncogenic clonal expansions and 
clonal hematopoiesis have also been demonstrated in old mice 
(75, 76). Notably, the incidence of leukemias is higher in individ-
uals with chronic inflammatory disease (77), although the cause 
of this association is unknown. Moreover, prophylactic aspirin 
use has been shown to reduce the incidence of colorectal cancer, 
breast cancer, and leukemias (78–80). Interestingly, polymor-
phisms associated with reduced inflammation are preferentially 
found in centenarians (81, 82).
Importantly, our studies provide a potential explanation for 
the mechanism underlying increased oncogenic clonal evolu-
tion and leukemias in old age. We demonstrated that the onco-
genes BCR-ABL, NRAS, and Myc can reverse aging-associated 
functional defects in B progenitors, promoting selection for 
progenitors expressing these oncogenes specifically in the aged 
hematopoietic context. These oncogenes do not restore differ-
entiation and likely convey other transformed phenotypes to the 
recipient cells. However, in the BM microenvironment of anti-
inflammatory aged mice, selection for NRASV12 was completely 
suppressed. We propose that the maintenance of hematopoietic 
progenitor fitness in both young and antiinflammatory, aged 
backgrounds can prevent oncogenic adaptation via stabilizing 
selection (35, 83). While oncogenic NRAS can restore fitness 
parameters (such as for signaling) in B progenitors (whether 
young or old) in an old hematopoietic background, it does not 
do so for progenitors in either young microenvironments or old 
but antiinflammatory microenvironments, as there appears to 
be little room for improvement.
In conclusion, our study demonstrates that aging is character-
ized by reductions in key parameters of B progenitor cell fitness 
and increased selection for oncogenic events, both of which are 
substantially modulated by the degree of aging-associated inflam-
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Statistics
Unpaired t tests, Cox proportional hazards tests, and 1-way ANOVA 
were used to analyze the data, with a P value of less than 0.05 con-
sidered statistically significant. All error bars represent biological rep-
licates (different mice), not technical replicates. Statistical analyses 
were performed with GraphPad Prism software, version 6.07 (Graph-
Pad Software). All results are expressed as the mean ± SEM.
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dissolved in PBS) for 2 hours. After 2 hours, mice were sacrificed, and 
106 BM cells were collected and surface stained to identify pro–, pre–, 
and immature B cell progenitor populations. After staining, cells were 
washed once with 1× PBS and the pellets resuspended in 100 μl Click-
iT fixative (Life Technologies) for 15 minutes at room temperature. 
After fixation, cells were again washed and incubated for 10 minutes 
in 50 μl diluted Click-iT saponin-based permeabilization solution (Life 
Technologies). After the 10-minute incubation period, 250 μl reaction 
mix (including 1× PBS, CuSO4, Alexa Fluor 647, and reaction buffer 
additive, combined following the manufacturer’s protocol) was added 
to each sample and incubated for 30 minutes at room temperature. 
Next, cells were washed and resuspended in 1× PBS containing 50 μg/
ml PI (Roche). Samples were run on a Gallios cytometer (Beckman 
Coulter). The normalized x-mean mean fluorescence intensity (MFI) 
of EdU+ cell populations (which is a measure of S-phase progression) 
was calculated using the following formula: [(x-mean MFI of EdU+ 
cells) – (x-mean MFI of the G1 population)].
Flow cytometric analysis
Surface staining. Single-cell suspensions were plated in 96-well 
round-bottomed plates and washed in FACS buffer containing 3% 
FBS, 1× PBS, and 2 mM EDTA (vol/vol). After washing, cells were sur-
face stained for 1 hour on ice to identify the hematopoietic cell popu-
lation of interest (cells were stained in 50 μl Ab solution). Cells were 
washed once with 200 μl FACS buffer and resuspended in 400 μl FAC 
S buffer for ﬂow cytometric analysis.
The following anti-mouse Abs were used: phycoerythrin-conju-
gated (PE-conjugated) anti-B220 (BD Pharmingen; catalog 553090), 
anti-CD43 (BD Pharmingen; catalog 553271), anti-CD4 (eBiosci-
ence; catalog 12-0041-82), anti-CD8 (eBioscience; catalog 12-0081-
82), anti-Ter119 (eBioscience; catalog 12-5921-81), anti-CD48 (BD 
Pharmingen; catalog 557485), anti-MAC1 (BD Pharmingen; cata-
log 557397), and anti-CD45.2 (BD Pharmingen; catalog 560695); 
PE-Cy7–linked anti-MAC1 (eBioscience; catalog 25-0112-82), anti–
IL-7Rα (eBioscience; catalog 25-1271-82), anti-CD45.1 (eBiosci-
ence; catalog 25-0453-82), and streptavidin (eBioscience; catalog 
25-4317-82); allophycocyanin-linked anti-B220 (eBioscience; cat-
alog 17-0452-82), anti-Sca1 (eBioscience; catalog 17-5981-82), and 
anti-CD150 (eBioscience; catalog 17-1502-80); Pacific Blue–linked 
streptavidin (e450) (eBioscience; catalog 48-4317-82) and anti-CD93 
(eBioscience; catalog 48-5892-80); FITC-conjugated anti–c-KIT (BD 
Pharmingen; catalog 553354); and biotin-linked anti-CD93 (eBiosci-
ence; catalog 13-5892-82). Flow cytometric analysis was performed 
on a CyAn, Cytomics FC 500, or Cell Lab Quanta SC flow cytome-
ter (all from Beckman Coulter). B cell progenitors were defined on 
the basis of their expression of surface markers: pro–B cells: B220lo, 
CD93hi, CD43hi; pre–B cells: B220lo, CD93hi, CD43intermed/lo; imma-
ture B cells: B220hi, CD93neg, CD4neg. Cell sorting was performed on 
MoFlo XDP 70 and 100 cell sorters (Beckman Coulter).
Intracellular staining. Intracellular cytokine staining was per-
formed as previously described (16). The following BD Biosciences 
PE-conjugated Abs were used: p-STAT3 (P-Y705, catalog 612569), 
p-STAT5 (P-Y694, catalog 612567), p-ERK1/2 (P-T202/P-Y204, cat-
alog 612566), and control (rat IgG2b, catalog 556925). Anti–TNF-α 
PE-conjugated Ab (BioLegend, catalog 506305) was used for the 
detection of TNF-α. Stained cells were analyzed on the CyAn ADP 
Analyzer (Beckman Coulter).
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